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A B S T R A C T
Purpose: Pharmacotherapy of epilepsies is limited due to low concentrations at epileptogenic foci, side
effects of high systemic doses and that some potentially efﬁcient substances do not pass the blood–brain
barrier. To overcome these limitations, we tested the efﬁcacy of local valproate (VPA)-containing
polymer implants in a model of necocortical injected tetanus toxin (TeT) in the rat.
Methods: Tetanus toxin was injected intracortically and cobalt (II) chloride (CoCl2) was applied on the
cortical surface. Video-electrocorticography recordings with intracortical electrodes were performed.
VPA-containing polymers were implanted above the cortical focus. Antiepileptic effects were evaluated
as reductions of epileptiform potentials (EPs) per hour in comparison to saline (NaCl)-containing
polymer implants.
Results: Triple 50 ng TeT injections plus CoCl2 application (20/10 mg) showed consistent EPs. NaCl-
implanted animals (n = 6) showed a mean of 10.5 EPs/h after the ﬁrst week, the EP frequency increased to
53.5 EPs/h after the second week. VPA-implant animals (n = 5) showed a reduction in EP frequency from
71.6 to 4.8 EPs/h after the second week. The EP frequency after the second week was higher in the NaCl-
implanted animals than in the VPA-implanted (p = 0.0303). The mean EPs/h increase in NaCl-implanted
rats (+42.9 EPs/h) was different (p = 0.0087) from the mean EPs/h decrease in VPA-implanted rats
(66.8 EPs/h).
Conclusion: Despite former publications no clear seizures could be reproduced but it was possible to
establish focal EPs, which proved to be a reliable marker for epileptic activity. Local antiepileptic therapy
with VPA has shown efﬁcacy in decreasing EP frequency.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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It is well known that approximately 0.5–1% of the worldwide
population suffers from epilepsy [1,2]. About 20–30% of those
epilepsies are refractory to pharmacological treatment [1,3,4].* Corresponding author. Tel.: +49 69 6301 5939; fax: +49 69 6301 7175.
E-mail address: freiman@med.uni-frankfurt.de (T.M. Freiman).
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Medical Center, Albert-Ludwigs-University, Breisacher Straße 64, 79106 Freiburg
im Breisgau, Germany
http://dx.doi.org/10.1016/j.seizure.2015.05.002
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reA high percentage of these pharmacoresistant epilepsies are
caused by acquired or maldevelopmental cortical lesions. In
these cases the development of new antiepileptic drugs (AEDs)
has not shown a convincing breakthrough [5]. For many of those
patients the surgical removal of these lesions improves the
epileptic outcome [6]. However, if the epileptogenic lesion or
focus is located in an eloquent brain area, surgery might result in
a severe neurological deﬁcit. For these patients, local antiepilep-
tic pharmacotherapy with AED-containing implants could be a
treatment option if experimental studies show an effect on
epileptic activity.served.
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is concentrated highly enough. However, in systemic pharmaco-
therapy, systemic adverse effects arising outside of the epileptic
focus may prevent sufﬁciently high AED concentrations in the
focus. Several drugs with potential antiepileptic properties cannot
reach the epileptogenic brain area because they do not pass the
blood–brain barrier [7,8]. In addition, pharmacoresistant epilep-
sies are often characterized by multiple drug transporters, which
prevent a sufﬁcient AED concentration in the focus [9,10]. In
contrast, local application of AEDs would advantageously reduce
systemic side effects, bypass the blood–brain barrier and diminish
the effect of multiple drug transporters by higher local AED
concentrations [11,12].
It was shown that intracerebral or intraventricular application
of AEDs as polymer implants or pump systems can reduce seizure
frequency or severity [13–16]. In a rat model with intracortical
tetanus toxin (TeT) injection Nilsen et al. [17] showed ictal and
interictal activity which was quantiﬁed by electrocorticography
(ECoG) and electromyography (EMG). Thus, these authors demon-
strated this model to be potentially suitable for measuring effects
of a local antiepileptic therapy. In further experiments, the same
group then described an antiepileptic effect of locally applied gap-
junction blockers [18].
The aim of the present study was to reproduce the described
neocortical TeT-injection epilepsy model by Nilsen et al. [17,18]
and establish an ECoG-based quantiﬁcation method for measur-
ing the epileptic activity in this model. If no stable, quantiﬁable,
epileptic activity could be established, this model should be
improved by applying more TeT or multiple TeT-injections; or
even combine this model with another neocortical model, as the
cobalt(II) chloride (CoCl2)-cortical application. Finally, if a
stable, quantiﬁable, epileptic focus would be established, it
could prove a potential therapeutic effect of locally applied
valproate (VPA)-containing biodegradable polycaprolactone
(PCL)-implants.
2. Materials and methods
Animal experiments were carried out according to the
European Community Council Directive (86/609/EEC) and the
Declaration of Helsinki and were approved by the local govern-
ment representative (Regierungspra¨sidium Baden-Wuerttemberg,
Freiburg, registration no.: 35/9185.81/G-09/10). Sixty-three male
Sprague-Dawley rats (Animal facility of the University Medical
Center Freiburg) at a mean age of approximately two and a half
months were included. Four different treatments were performed:
no toxin, single injection of 50–200 ng TeT, triple injections of
50 ng TeT or triple injections of 50 ng TeT plus either 20 mg
(initially) or 10 mg (afterwards) CoCl2.
2.1. Surgery
Surgery was conducted upon sterile conditions. Sprague-
Dawley rats were anesthetized with 1.5–2.5% vol. isoﬂurane and
placed in a stereotactic frame (David Kopf instruments, Tujunga,
CA). Borehole trephinations were performed (Proxxon, Niersbach,
Germany) and the dura mater was perforated with a needle.
Injections were performed over a stainless steel cannula (outer
diameter, 0.28 mm), connected to a 2 mL microsyringe (Hamilton,
Carl Roth GmbH and Co. KG, Karlsruhe, Germany) via PE-20 tubing
with a micropump (World Precision Instruments, Sarasota, USA).
For ECoG recordings, teﬂon-coated silver electrodes (diame-
ter = 0.38 mm, World Precision Instruments, Sarasota, USA) with
de-insulated endings were utilized.
In rats without injection, two ECoG electrodes were placed into
the M1 region of the right hemisphere (coordinates in relation tothe bregma; [19]): no. 1: anteroposterior (AP) +1.1 mm, medio-
lateral (ML) 2.5 mm, dorsoventral (DV) 1.0 mm; no. 2: AP
+1.1 mm, ML 1.5 mm, DV 1.0 mm. EMG electrodes were
inserted into the right and left temporal muscle. The reference
and grounding electrode were initially placed into the cerebellum,
later placed intraosseously by attachment to implanted screws,
which were positioned over the right and left parietal cranium,
serving for additional stability. All electrodes were connected to a
plug connector, which was embedded in dental cement together
with the screws (Paladur1, Heraeus, Hanau, Germany). All animals
in this investigation received 5 mL 0.9% saline (NaCl) solution
subcutaneously during surgery for ﬂuid replacement and 0.05 mg/
kg bodyweight buprenorphine subcutaneously after surgery to
prevent postoperative pain.
In rats receiving a single injection of 50–200 ng TeT, the toxin
was injected into the M1 area of the right hemisphere (AP +1.1 mm,
ML 2.5 mm; DV 1.0 mm) over a 5-min period. Fifty nanogram
TeT were solved in 0.5 mL sterile distilled water with 2% bovine
serum albumin resulting in a working concentration of 100 ng/mL.
In the case of Evans blue-injection, the toxin was solved in 0.25 mL
Evans blue solution and 0.25 mL sterile distilled water with 2%
bovine serum albumin. To ensure appropriate toxin diffusion
10 min had to elapse after injection. Then the ECoG and EMG
electrodes were positioned as described above.
For rats with triple injections of 50 ng TeT, the additional
boreholes were AP +2.1 mm, ML 3.5 mm and AP +0.1 mm, ML
3.5 mm. Each injection was performed over a 10-min period to
ensure toxin diffusion. Electrode positioning followed as
described above.
For rats with triple injections of 50 ng TeT plus 20 mg or 10 mg
CoCl2, a hole (5 mm diameter) was carefully drilled with a mill in
the skull above the right primary motor cortex (anterior to the
bregma, with edges 1 mm lateral to the midline and bordering the
coronal suture; Fig. 1A). Drilling was performed upon steady saline
cooling to avoid heat. The dura mater was removed with a sharp
miniaturized hook. TeT (50 ng) was injected at injection sites
described for the animals with triple injections (Fig. 1B). After the
injections, 20 or 10 mg crystalline CoCl26H2O was applied onto the
cortex. Afterwards, a biodegradable PCL-implant containing either
0.9% NaCl or VPA (10%, w/w each) was placed on top. Finally, the
electrodes and the lesion site were covered with cyanoacrylate
(Fig. 1D), that did not get in touch with the cortical surface.
Production and release kinetics of the implants were described in
detail by Kammerer et al. [20]. Rats treated with TeT or CoCl2
showed an increased irritability to noise, physical contact, toward
other rats or the hand of the examiner. In addition, they showed an
increased aggression. These signs were also described by Brener
et al. [21] and Liang et al. [22].
2.2. Recordings, data analysis and histology
In all animals a combined ECoG/EMG-video-monitoring was
performed. Recordings started two days after surgery at the
earliest to allow recovery and lasted between 90 min and 6 h each.
After ampliﬁcation, data were acquired using a bandpass ﬁlter
(1 Hz to 5 kHz) and sampled by CED Spike 2 software version 5
(Cambridge Electronic Design Ltd. Cambridge, U.K.). The recordings
were analyzed by blinded analyzers, i.e. they did not know which
treatment the animal had received. The analysis focused on
qualitative and quantitative evaluation of both interictal and ictal
activity. Efforts were made not to mistake artifacts for epileptic
activity. Interictal epileptic activity was deﬁned as unambiguous
epileptiform potentials (EPs) characterized by single or multiple
spikes followed by a slow wave and clearly interrupting
background activity with respect to amplitude and frequency
(Figs. 4B and 5). EPs were previously described after TeT injections
Fig. 1. Combined triple tetanus toxin injections and cobalt(II) chloride application. (A) View on the burr hole on the right frontal cranium next to the bregma (BR). The
meninges were removed with a dural hook. (B) Tetanus toxin injection. (C) Positions of the six electrodes, placed in the right motorcortex (electrocorticogram, ECoG), left and
right temporal muscle (electromyogram, EMG R/L) or adjacent to a screw for reference (REF) and grounding (GND). (D) Electrode placement after cobalt(II) chloride
application and implant insertion. (E) Electrode ﬁxation in plug connector after surgery.
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seizure patterns consisted of runs of repetitive spike-waves or
rhythmic activity with a dynamic evolution in frequency and
topography (Figs. 3 and 4A).
For histology animals were anesthetized intraperitoneally with
ketamine, 100 mg/kg, xylazine 5 mg/kg, atropine 0.1 mg/kg in 0.9%
NaCl and transcardial perfused for 5 min with artiﬁcial cerebro-
spinal ﬂuid (ACSF: 125 mM NaCl, 25 mM NaHCO3, 2.5 mM KCl,
1.25 mM NaH2PO4, 25 mM C6H12O6, 2 mM CaCl2, 1 mM MgCl2),
thereafter for 10 min with 4% paraformaldehyde in 0.1 M
phosphate buffer at pH 7.3. Immediately after surgical removal
the brain specimen were cut perpendicular to the rostro-caudal
axis into sections of 50 mm (vibratome VT 1000S, Leica, Bensheim,
Germany). Afterwards sections were immersion-stained for
10 min in 0.1% cresyl violet, dehydrated in increasing concentra-
tions of ethanol, xylol and coverslipped (Immu-Mount, Thermo-
Shandon, Dreieich, Germany), for details see ref. [24]. In
histological sections the TeT injected rat brains, even those with
multiple injections, did not show any morphological lesion, despite
the opened scull and perforated dura mater (data not shown),
which has been described by multiple authors [17,18,21–
23,25,26]. In contrast animals treated with neocortical CoCl2
showed an extended necrosis (Fig. 6).2.3. Statistics
Assuming that there is no normal distribution in the amount of
EPs/h, a Mann–Whitney U test was performed to compare the
effect of VPA and NaCl. A p-value less than 0.05 was considered
signiﬁcant.
2.4. Histology
After decapitation, the brain was transferred to 4% paraformal-
dehyde in 0.4 M phosphate buffer, pH 7.4. Sections (70 mm) were
prepared with a vibratome (Leica VT 1000S) for Nissl staining
(microscope: Axioplan2, software: AxioVision Rel 4.8 Carl Zeiss,
Oberkochen, Germany).
2.5. Drugs
Buprenorphine hydrochloride (Temgesic1, Reckitt Benckiser
Healthcare Ltd., Hull, United Kingdom); cobalt(II) chloride 6H2O,
Evans blue (Sigma–Aldrich, Steinheim, Germany); isoﬂurane
(Forene1, Abbott GmbH and Co. KG, Wiesbaden, Germany); 0.9%
NaCl and VPA (10%, w/w each) PCL-implants (Freiburg Materials
Research Center FMF, Albert-Ludwigs University, Freiburg,
Fig. 3. Electrocorticogram (ECoG) and electromyogram (EMG) of the sole recorded
seizure after single tetanus toxin injection. (A) Rhythmic spike-waves with evolving
frequency and amplitude. The termination of this seizure pattern in the ECoG
(inclined arrow) coincided with the termination of the tonic–clonic seizure. The
high ECoG amplitudes transmitted their signal into the EMG electrodes. (B)
Expanded view for the marked range from (A).
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Surrey, U.K.).
3. Results
3.1. Recordings in rats without injection
In 10 animals ECoG electrodes were implanted only to record
physiological baseline ECoG. Recorded activity included a basic
rhythm consisting of alpha, beta, theta, and delta waves with
amplitudes of about 200 mV (Fig. 2). In contrast to incidental
spiking in the control animals reported by Nilsen et al. [17], no
epileptiform activity was observed.
3.2. Recordings in rats with single injection of 50–200 ng TeT
In ﬁve animals a single dose of 50 ng TeT was intracortically
injected into the primary motor cortex of the right hemisphere
through a borehole; ﬁve animals served as controls and received
the same amount of saline (0.9%) instead. The NaCl-injected
animals did not show any difference in their behavior or their ECoG
and EMG recordings compared with the rats without any injection.
In 10 animals we added Evans blue to the TeT injections and saw
the intracortical diffusion of the toxin adjacent to the injection site
macroscopically. In further 10 animals higher doses up to 200 ng
per single injection were administered. Surprisingly, the ECoG and
EMGs were not different from the control animals; in particular no
constant epileptiform activity was seen. However, there was one
single incidental seizure in one animal recorded on the 46th
postoperative day (Fig. 3). The seizure started with facial twitching,
followed by clonic movements of the upper and lower limbs. The
corresponding rhythmic spike-waves in the ECoG terminated at
the same time point, when the 81 s period of the seizure also
stopped.
3.3. Recordings in rats with triple injections of 50 ng TeT
Eight animals were triple injected intracortically with 50 ng TeT
over three boreholes; another animal was triple injected with
saline (0.9%). Three of the eight animals with triple TeT injections
died shortly after surgery.
Only one of the remaining ﬁve triple TeT-injected animals
had recurrent seizures (Fig. 4A). These seizures started on the
second postoperative day and lasted until the spontaneous death
on the 10th day. The majority of these seizures manifested
clinically with clonic movements, including the head and (left)
forelimb. There were also some subclinical seizure patterns. In
the ECoG and EMG, repetitive spike-waves with increasing
frequency were observed. Another animal had a single subclini-
cal seizure, as seen by runs of repetitive spike-waves in the
ECoG. Two other animals, of which one had many EPs, displayed
only single clonic jerks, which appeared as an involuntary headFig. 2. Electrocorticogram (ECoG) and electromyogram (EMG) from an animal without inj
2 (medial to 1) show physiological activity predominantly in the theta range. The EMGs
view for the marked range from A). Amplitudes shown on the y-axis in microvolt (mVmovement and followed single spike-waves (Fig. 4B). The last
animal with triple TeT injections did not develop any epilepti-
form activity.
3.4. Recordings in rats with triple injections of 50 ng TeT and topically
administered CoCl2
Six animals with triple 50 ng TeT injections additionally
received 20 mg CoCl2 that was placed topically on the neocortical
surface. In three of these animals, a VPA-containing PCL-implant
was subsequently implanted with contact to the cortical surface.
The remaining three animals served as controls; here a sham PCL-
implant with NaCl was inserted. Three animals – two with NaCl-
implants and one with a VPA-implant – died during the ﬁrst night
after surgery. All remaining animals showed EPs in the ECoG
recordings (Fig. 5).
In the NaCl-implant animal, EPs occurred after three days and
increased in frequency until the second week, when the frequency
amounted to 271.4 EPs/h. After three weeks the EP frequency
declined and ﬁnally vanished after six weeks. The EP frequency of
the two remaining VPA-implant animals peaked (30 and 87 EPs/h)
during the ﬁrst days, then declined gradually until the EPs
disappeared after three weeks. In contrast to sole triple TeT
injections, triple TeT injections plus CoCl2 treatment resulted in
severe necrosis, spreading from the cortical M1 and M2 region to
the basal ganglia (Fig. 6). The contralateral hemisphere was not
affected. Because of the high mortality in the group with additional
20 mg CoCl2, the dose was reduced to 10 mg.
Eight animals were triple injected with 50 ng TeT and 10 mg
CoCl2 was placed neocortically. Thereafter, ﬁve animals received
sham NaCl-implants and three received VPA-implants. None of
these animals died shortly after operation, and all but one (VPA-
implant) developed EPs (Fig. 5). The NaCl-implanted animals
showed EPs after the ﬁrst days and the EP frequency climaxed
during or after the second week (9.6–35.0 EPs/h), then gradually
declined. In the two VPA-treated animals with EPs, the EP
frequency also peaked after few days (341.3 or 15.7 EPs/h after
one week, respectively), but already declined during the second
week. The last VPA-treated animal did not show any EPs at all.ection and no epileptic activity. (A) ECoG electrode 1 (area M1 right hemisphere) and
 did not show any activity of the left (L) or right (R) temporal muscle. (B) Expanded
). Timescale shown on the x-axis in seconds (sec).
Fig. 4. Electrocorticogram (ECoG) and electromyogram (EMG) recordings from seizures and interictal spike-waves after triple tetanus toxin injections. (A) tonic–clonic seizure
as presented by repetitive spike-waves with increasing frequency. (B) Interictal spike-waves in the ECoG, which were not followed by contractions of the temporal muscle in
the EMG.
Fig. 5. Spike-waves after triple injections of 50 ng tetanus toxin and cobalt(II) chloride application on the neocortical surface. (A) The double approach produced consistent
interictal spike-waves in all (except for one VPA-treated) animals but no seizures. (B) Expanded view of interictal spike-waves (arrows).
M.P. Rassner et al. / Seizure 30 (2015) 6–1310Performing a two-way analysis of variance (factor I: 20 or 10 mg
CoCl2; factor II: week 1 or 2), no hints were obtained indicating that
results on EP frequency differ between 20 or 10 mg treated animals
(factor I: p = 0.8127). Therefore the results of 20 or 10 mg CoCl2-
treated animals could be pooled together. There was, however, a
high interindividual inconsistence in the triple TeT-injected plus
CoCl2-treated animals regarding the amount of EPs/h. The EP
frequencies after the ﬁrst week in the NaCl-implanted animals
(mean: 10.5 EPs/h, standard error of the mean [SEM] 4.8; n = 6;
median: 6.4 EPs/h) and VPA-implanted animals (mean: 71.6 EPs/h,
SEM 67.5; n = 5; median: 4.6 EPs/h)), therefore, did not differFig. 6. Nissl-stained histology of the neocortex after triple injections of 50 ng
tetanus toxin and application of 20 mg cobalt(II) chloride. Necrosis on the
application site (R, right), but no affection of the contralateral side. CC: corpus
callosum; CP: caudate putamen; EC: external capsule; LV: lateral ventricle; M1:
primary motor cortex; M2: secondary motor cortex. Scale bars 1 mm.signiﬁcantly, though the mean EP frequency of VPA-implant
animals was higher than for NaCl-implant animals. The mean and
median EP frequency after the second week was, however,
signiﬁcantly higher (p = 0.0303) in the NaCl-implant animals
(mean: 53.5 EPs/h, SEM 34.9; median: 22.0 EPs/h) than in the
VPA-implant (mean: 4.8 EPs/h, SEM 2.2; median: 6.7 EPs/h)
animals (Fig. 7A).
The time course of EP frequencies were similar within each
implant group: The EP frequency of the NaCl-implant animals
increased in the second week, while the VPA-implant animals
showed a reduction in their EP frequency in the second week.
Comparison between the mean increase in EPs/h of the NaCl-
implant animals (+42.9, SEM 32.7) and the mean decrease in EPs/
h of the VPA-implant animals (66.8, SEM 65.9) resulted in a
signiﬁcant difference (p = 0.0087) between the rates (Fig. 7B).
This was also true for the 10 mg CoCl2 treated animals alone
(5 NaCl-implanted animals vs. 3 VPA-implanted animals;
Fig. 7C).
4. Discussion
The aim of our study was to establish an animal model for
neocortical epilepsy and to test whether a neocortically placed
PCL-implant loaded with an AED would reduce seizure frequency
and epileptic ECoG activity. According to the literature, the rat TeT
epilepsy model is an appropriate model for chronic neocortical
epilepsy [25]. In particular following the publications of Nilsen
et al. [17,18], we saw the chance to establish a model where ictal
and interictal ECoG activity could easily be quantiﬁed.
4.1. Single injection of TeT
In our hands the model proved to be most difﬁcult in producing
stable seizure frequencies or epileptiform ECoG activities. Despite
using the same rat strain, TeT source, injection locus and ECoG
electrode positioning combined with temporal muscle EMG
recordings as Nilsen et al. [17], we were not able to reproduce
Fig. 7. Efﬁcacy of VPA-loaded polymer-implants in reducing the frequency of epileptiform potentials (EPs). (A) The EP frequency after the second week was lower in VPA-
treated (n = 5) animals than in saline-treated (n = 6) animals (20 or 10 mg cobalt(II) chloride; CoCl2). (B) The increase or decrease of EPs between the ﬁrst and second week
were compared. Whereas saline-implanted animals (n = 6) showed an increase of EPs/h, VPA-implanted rats (n = 5) showed a decrease. (C) The increase or decrease of EPs
differed also between saline-treated (n = 5) and VPA-treated (n = 3) animals without the data from the animals with 20 mg CoCl2. Signiﬁcant differences are indicated by
asterisks: *p < 0.05, **p < 0.01; SEM: standard error of the mean.
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Evans blue and increasing the dose per single injection up to
fourfold without any relevant effect, we also tested the efﬁcacy of
the used TeT batch in vitro: The toxin clearly reduced the
exocytotic release of 3H-glutamate [27] and of 3H-GABA [28] in
both rat and human neocortical synaptosomes previously loaded
with the corresponding transmitter.
Nilsen et al. [17] deﬁned epileptic activity as an abrupt change
of background ECoG activity, followed by a burst of fast activity
evolving into rhythmic spike discharges with higher amplitudes.
Spike-waves were not described (though observed previously after
TeT injection; [21,23]). We were not able to reproduce these
features in ECoG activity between our controls and the single-dose,
50–200 ng TeT injected rats. We observed one single tonic–clonic
seizure in only one of 25 single TeT-injected rats, whose ECoG
during the seizure was unambiguously different to the description
of epileptic activity of Nilsen et al. [17]. Barkmeier and colleagues
described also in two publications that seizures were extremely
rare [29,30].
Consecutively, we were also not able to reproduce the
differences in the power spectra derived from Fast Fourier
Transformation of ECoG activity, which should show power
elevation in the 5–20 Hz spectrum [17]. A power elevation in
the 5–20 Hz spectrum was seen in control and in injected animals.
In the beginning of our experiments the frequency and
amplitude of the EMG activities seldom differed from those of
the ECoG recordings. By transposing the grounding and reference
electrode intraosseously in the scull, we could improve the ECoG
signal (compare Figs. 3 and 5). We therefore assume that, to some
degree, activity recorded in the ECoG channels was actually
originating in muscles and registered by both EMG and ECoG
electrodes. Therefore, care has to be taken, that muscle activity is
not mistaken with ictal activity in the ECoG.
4.2. Triple injection of TeT
Because we were not successful with single TeT injections, even
when administering higher doses, we enlarged the injection
surface area with a triple injection of 50 ng TeT over three burr
holes. This enabled us to produce visible seizures and differences in
the ECoG activity between TeT-injected animals and controls.
Instead of a high frequency activity [17], we observed clear-cut
interictal spike-waves. The rare seizures were characterized by
tonic–clonic movements of the extremities and by runs of
unambiguous repetitive spike-waves in ECoG recordings. Some-
times clonic jerks following single interictal discharges were
observed. In the control group, where the animals received a triple-
NaCl-injection, none of the animals showed EPs, therefore we
assume that the TeT but not the injection-trauma alone wasresponsible for the EPs. However, the effect on interictal epileptic
activity and seizures after triple injections of TeT varied
immensely, and such a high variability prevented the ﬁnal
establishment of an animal model of neocortical epilepsy for the
development of new treatment strategies. Therefore we decided to
use CoCl2 in addition to TeT.
4.3. Triple injection of TeT plus CoCl2
It was shown that (heavy) metals can produce epileptic foci (see
for instance [31–33]). In particular cobalt has been widely utilized
in rodent epilepsy models. The cellular mechanism of cobalt-
induced epilepsy is not known precisely and many possible
explanations for its proconvulsive properties have been proposed:
damage of inhibitory neurons [34,35], effects on postsynaptic
receptors and glutamate uptake [36,37], and activity-dependent
facilitation of gap junctions [38]. Eder et al. [39] described seizures
induced by intrahippocampal implantation of cobalt. Tamargo
et al. [40] applied 20 mg CoCl2 to the rat neocortex, resulting in
epileptic spikes in half of the animals, but observed an unspeciﬁed
high number of rats which died during status epilepticus. Chang
et al. [41] showed that implantation of a cobalt wire into the motor
cortex of rats produced subacute seizures that were observable for
three weeks.
However, despite the fact that these animals developed a local
necrosis in the injured area, the stable EP activity decreased after
four to six weeks, what was also described by Liang et al.
[22]. Unfortunately there is no good explanation why the epileptic
activity decreases, since other epilepsy models with morphologi-
cal lesions, as the hippocampus (e.g. applied kainiate or
pilocarpin), showed epileptic activity over a nearly unlimited
time. An answer could be, that the structure of a six-neuronal-
layer-thick neocortex has better antiepileptic repair mechanisms
then a three-layered hippocampus. This is supported by the fact,
that even TeT injections in hippocampus show EPs for month to
years [21,23,42,43].
In the present study, we did not produce overt seizures with
the additional CoCl2 treatment. In parallel experiments, however,
we used a larger TeT dose (225 ng), a medium CoCl2 dose (15 mg)
and also implanted NaCl- or VPA-implants  [44]. Then, the animals
developed reliable seizures, but also had a high mortality rate, so
that quantitative evaluation of ECoG activity was not possible
[44]. The CoCl2-implanted animals in the present study, however,
showed a stable activity of typical EPs, which enabled their
quantiﬁcation. We also observed a high mortality rate among the
animals treated with 20 mg CoCl2 and therefore decided to reduce
the dose to 10 mg. None of the animals treated with 10 mg CoCl2
died, but all except of one (treated with local VPA) developed
stable EPs.
M.P. Rassner et al. / Seizure 30 (2015) 6–1312The stable EP activity upon triple TeT-injections and
additional CoCl2 enabled us to test a local VPA treatment, an
antiepileptic drug commonly used in therapy of focal epilepsy.
We were able to show a reduction in the rate of EPs after
application of VPA directly on the epileptic focus. We hypothesize
therefore that local administration of VPA might positively
inﬂuence not only over-all survival [44], but also focal epilepsy.
However, the rate of EPs was highest during the ﬁrst two weeks.
Therefore we compared the effects of VPA and NaCl polymer
implants as an elevation or reduction of the frequency of EPs in
this stretch of two weeks, occurring seven and 14 days after the
implantation of VPA or NaCl, occurring within one week before
and after the implantation operation. The measurements and
operations were carried out before the forth week, since we
expected and experienced a drop of the frequency of the EPs after
this time point.
We admit that in the present study no animals with TeT
injections plus CoCl2 application were studied without PCL implant.
However, the fabrication of VPA PCL implants was described
previously [20]. We assume no further inﬂuence of the biodegrad-
able PCL implants themselves or of their minimal NaCl load. The
improbable role of the PCL implants themselves in epileptogenesis
(or its prevention), however, has not (yet) been examined
systematically.
It was shown by Kammerer et al. [20] in superfusion
experiments that the utilized VPA-containing PCL-implants
release about 88% of their VPA content in vitro already within
the ﬁrst four days; however, the course of the spiking
epileptogenic focus seemed to be affected over a longer period
in vivo. In our experiments the EPs frequency only slowly
diminished over a two weeks period in animals with VPA-
implants. A possible explanation for this could be that the
release of VPA out of the polymer matrix might be slower under
in vivo conditions (only one side of the polymer in contact with
the cortical surface, no steady perfusion) than in an in vitro
superfusion chamber.
5. Conclusions
After establishing a rat model with a stable interictal activity
upon triple TeT-injections and additional CoCl2, we could prove the
in principle antiepileptic effect of local AED treatment. We plan
further experiments to show its beneﬁcial effect also on ictal
activity including clinically relevant seizures.
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